Evaluating the response to glatiramer acetate in relapsing-remitting MS (RRMS) patients

Treatment, therapies and management

This prospective longitudinal study investigated if a previous scoring system (based on new MRI active lesions, relapses and sustained disability progression, and predicted patient disability progression over time) can be used in MS patients treated with glatiramer acetate (GA).

The study included 151 patients with relapsing remitting MS. The scores were based on clinical and MRI activity after one year of treatment and ranged from nought to three. They found that patients with a score of ≥ 2 and with clinical activity (with or without MRI activity) during the first year of treatment were at an increased risk of ongoing clinical activity in the next two years.
These patients could be candidates for an early therapeutic change with other drugs which may be more effective.

Authors: Río J, Rovira A
Source: Mult Scler. 2014 Mar 12. [Epub ahead of print]
Read the abstract


Latest MS research news

Main MS research areas

Challenges of MS research

Atacicept in multiple sclerosis: a randomised, placebo-controlled, double-blind, phase 2 trial